Dr. Tester's clinical research focuses on muscle-invasive bladder cancer (MIBC), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). He is actively involved in clinical trials, including the AMBASSADOR study, which investigates the use of pembrolizumab in MIBC, and the ALCHEMIST trial, which explores adjuvant therapies for early-stage lung cancer. Additionally, he has co-authored studies on circulating tumor cells as prognostic markers in metastatic castration-resistant prostate cancer.
William J. Tester, MD, FACP
Vice Chairman Clinical Operations
Director, Bladder Cancer Research
Contact Information
Honickman Center
1101 Chestnut Street
14th Floor
Philadelpphia, PA 19107
Vice Chairman Clinical Operations
Director, Bladder Cancer Research
RESEARCH & CLINICAL INTEREST
Education
Medical School
Drexel University College of Medicine, Philadelphia, PA 1977
Residency
Albert Einstein Medical Center, Philadelphia, PA 1980
Fellowships
National Institutes of Health Clinical Center, Bethesda, MD 1982
Georgetown University Hospital, Washington, DC 1983
Publications
- Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
- Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer
- Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
- Renal cell carcinoma: entering the age of biomarkers
- Tumor-associated antigen targets for novel immune-based strategies in prostate cancer